Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Keybanc Maintains Overweight on Olin, Raises Price Target to $61

Keybanc Maintains Overweight on Olin, Raises Price Target to $61

Keybanc analyst Aleksey Yefremov maintains Olin (NYSE:OLN) with a Overweight and raises the price target from $60 to $61.

byBenzinga Newsdesk

August 1, 2022

1 minute read

Keybanc analyst Aleksey Yefremov maintains Olin (NYSE:OLN) with a Overweight and raises the price target from $60 to $61.

Analyst Ratings

TD Cowen Maintains Outperform Rating for Oracle: Here’s What You Need To Know

By Benzinga Insights

June 13, 1:00 PM

TD Cowen has decided to maintain its Outperform rating of Oracle (NYSE:ORCL) and raise its price target from…

ORCL

Enveric Biosciences Announces New U.S. Patent For C4-Carboxylic Acid-Substituted Tryptamine Derivatives

By Happy Mohamed

September 5, 8:03 AM

New patent provides additional composition of matter and methods of use claims for Enveric's tryptamine-derived prodrugs including EB-373, a new chemical entity psilocin prodrug Enveric Biosciences (NASDAQ:ENVB)

ENVB

UBS Downgrades Lyft to Neutral, Lowers Price Target to $16

By Benzinga Newsdesk

September 26, 6:58 AM

UBS analyst Lloyd Walmsley downgrades Lyft (NASDAQ:LYFT) from Buy to Neutral and lowers the price target from $50 to $16.

LYFT

German American Q4 EPS $0.83 Misses $0.84 Estimate

By Michael Horton

January 30, 6:17 PM

German American (NASDAQ:GABC) reported quarterly earnings of $0.83 per share which missed the analyst consensus estimate of $0.84 by 1.19 percent. This is a 13.7 percent increase over earnings of $0.73 per share from the

GABC

Keybanc Maintains Overweight on Olin, Raises Price Target to $61

Related Posts

TD Cowen Maintains Outperform Rating for Oracle: Here’s What You Need To Know

Enveric Biosciences Announces New U.S. Patent For C4-Carboxylic Acid-Substituted Tryptamine Derivatives

UBS Downgrades Lyft to Neutral, Lowers Price Target to $16

German American Q4 EPS $0.83 Misses $0.84 Estimate